IMMUNOVANT INC (IMVT)
US45258J1025 - Common Stock
June 7th Options Now Available For Immunovant (IMVT)
Immunovant is Now Oversold (IMVT)
Interesting IMVT Put And Call Options For May 10th
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom.
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart.
Notable Thursday Option Activity: IMVT, DBRG, TITN
Immunovant Awarded U.S. Patent for IMVT-1402
Composition of matter patent issued with coverage until June 2043Patent also includes methods of use and methods of manufacturing claims NEW YORK, March...
Immunovant is Now Oversold (IMVT)
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential.
First Week of IMVT February 16th Options Trading
Immunovant GAAP EPS of -$0.36 beats by $0.07 (NASDAQ:IMVT)
Immunovant exceeds expectations with Q3 earnings as GAAP EPS beats estimates by $0.07.
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
Immunovant plans to initiate 4-5 potentially registrational programs for IMVT-1402 over the next fiscal year Immunovant plans to initiate trials in 10...
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
Unveil these standout Russell 2000 stocks, meticulously picked to harness the potential of the evolving market landscape in the 2024 surge.
Notable Friday Option Activity: WYNN, IMVT, CYTK
March 8th Options Now Available For Immunovant (IMVT)
3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024
Analyst ratings tell investors which stocks institutional investors like, here are three top-rated Russell 2000 stocks to consider in 2024
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
These five biotech companies could have a lot of room to run.
IMVT February 23rd Options Begin Trading
IMVT February 2024 Options Begin Trading
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
Despite a Wednesday tumble, the major indexes are right at 2023 highs.
Immunovant stock jumps 9% on positive data for Graves' disease drug (IMVT)
Immunovant (IMVT) stock jumped 9% in the wake of positive Phase 2 data for its drug candidate batoclimab in the treatment of Graves' disease. Read more here.
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
Immunovant reversed its fortunes Thursday following an Argenx-tied selloff Wednesday.
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for...
Argenx Dives On Autoimmune Therapy Failure
A treatment for a skin-blistering condition failed to beat a placebo.
Notable Friday Option Activity: ORCL, DAL, IMVT
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Software earnings were strong, while the Fed is shifting toward rate cuts.
Interesting IMVT Put And Call Options For January 2024
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential